-
2024-515459-39-00
7
2025-05-08
Advanced or Metastatic Squamous Solid Tumors
-
2024-511435-10-00
1
2025-04-30
Hepatocellular Carcinoma
-
2024-515793-27-01
5
2025-04-30
HIV
-
2024-510893-25-00
5
2025-04-29
Brain metastases of cancer > brain radionecrosis
-
2024-517582-16-00
5
2025-04-14
rapid sequence induction in the operating room
-
2024-516363-92-00
5
2025-04-08
Psychosis Associated with Alzheimer’s Disease
-
2023-508507-20-00
5
2025-04-03
Locally advanced or metastatic conventional chondrosarcoma with an IDH
-
2024-513862-20-00
5
2025-03-26
Chronic Rhinosinusitis with Nasal Polyposis
-
2024-516219-25-00
5
2025-03-25
psoriatic arthritis
-
2023-503326-39-00
5
2025-03-06
Synchronous oligometastatic non-small cell lung cancer (NSCLC)
-
2023-506656-24-00
5
2025-02-12
Myasthenia gravis
-
2024-516306-28-00
10
2025-02-12
Autism with Spectrum Disorders and Moderate to Severe Intellectual Dis
-
2024-511442-39-00
5
2025-02-05
Rheumatoid arthritis (RA)
-
2023-505320-54-00
4
2025-01-30
Multiple System Atrophy
-
2023-505570-15-00
4
2025-01-29
Congenital Ichthyosis
-
2023-503520-31-00
4
2025-01-15
Immunocompromised patients with PML (with an underlying cause of immun
-
2023-504893-39-00
10
2025-01-14
Comatose Traumatic Brain Injury patients
-
2023-506942-22-01
4
2025-01-10
paraneoplastic sensory neuropathy with anti-Hu antibodies
-
2023-508794-83-00
4
2025-01-10
Epidermolysis bullosa simplex
-
2023-507544-37-00
5
2025-01-08
patients with end-stage renal disease on chronic peritoneal dialysis a
-
2023-506350-21-00
4
2025-01-06
Localized, resected, FIGO stage I (2018 classification), uterine leiom
-
2024-515457-21-00
3
2024-12-30
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI